These outcomes will support a phase 2 clinical study of ALKS 37, that may assess the safety, tolerability and efficacy of ALKS 37 in people with OIC. The phase 2 study is expected to begin in the first half of calendar 2010. SOURCE Alkermes, Inc.. Alkermes initiates multidose Stage 1 clinical research of ALKS 37 for OIC Alkermes, Inc. announced the initiation of a multidose phase 1 clinical research of today ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the consequences of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation .Despite garlic’s popularity, the compounds in charge of its pungency, along with the receptors through which we perceive those substances, have remained unknown. Within their new function, the researchers found that raw, however, not baked, garlic was with the capacity of eliciting responses from two so-called TRP stations, TRPV1 and TRPA1, which belong to an extraordinary family of receptors that can be activated by chemicals and temperature. Some TRP stations, including TRPV1 and TRPA1, respond to both temperatures and chemical substances: TRPV1 is known to respond to noxious warmth and to the pungent element of chili peppers, whereas TRPA1 is usually activated by noxious cold and by pungent substances within cinnamon oil, mustard essential oil, and wintergreen essential oil.